RS
TSHA icon

R Squared’s Taysha Gene Therapies TSHA Stock Holding History

R Squared’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,276
Closed -$50.4K – 692
2026
Q1 		$50.4K Buy
+11,276
New +$52.4K 0.03% 417
2025
Q4 		– Sell
-16,094
Closed -$52.6K – 718
2025
Q3 		$52.6K Buy
+16,094
New +$45.6K 0.02% 487
2025
Q1 		– Sell
-130
Closed -$225 – 1428
2024
Q4 		$225 Buy
+130
New +$270 ﹤0.01% 1556

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R Squared's TSHA Position: Q2 2026 in Review

R Squared sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 11,276 shares — an estimated $50.4K sold.

R Squared first reported a position in TSHA in Q4 2024 and held it in 3 quarters. The position peaked at $52.6K in Q3 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • R Squared reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • R Squared sold 11,276 Taysha Gene Therapies shares in Q2 2026, an estimated $50.4K.
  • R Squared first reported a position in Taysha Gene Therapies in Q4 2024 and held it in 3 quarters.
  • R Squared's Taysha Gene Therapies position peaked at $52.6K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.